MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jgs.70754

Медицинская библиотека · Journal of the American Geriatrics Society · 2026

Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z-Drugs: A Target Trial Emulation.

Matsuo Yuichiro, Yamana Hayato, Sasabuchi Yusuke, Matsui Hiroki, Kohro Takahide, Yasunaga Hideo

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z-drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study aimed to examine whether lemborexant and suvorexant are associated with a lower risk of hip fracture than Z-drugs in older individuals.

METHODS

We conducted a cohort study using databases from Tochigi Prefecture, Japan. We included individuals aged ≥ 65 years who newly initiated either lemborexant or Z-drugs (lemborexant analysis cohort) or either suvorexant or Z-drugs (suvorexant analysis cohort). The primary outcome was hospitalization for hip fracture within 1 year of cohort entry. Per-protocol effects of continuous treatment with the assigned drugs were estimated. Baseline confounding was adjusted using inverse probability of treatment weighting based on propensity scores. Censoring due to discontinuation of the assigned drug or switching to the comparator drug was adjusted for using inverse probability of censoring weights. Adjusted cumulative incidence and hazard ratios (HRs) were estimated using the Kaplan-Meier methods and Cox regression, respectively.

RESULTS

The lemborexant analysis cohort included 22,655 individuals (6879 and 15,776 in the lemborexant and Z-drug groups, respectively). After adjustment, lemborexant use was associated with a significantly lower hip fracture incidence (HR, 0.31, 95% confidence interval [CI], 0.16-0.59, p < 0.001). The suvorexant analysis cohort included 22,377 individuals (6699 and 15,678 in the suvorexant and Z-drug groups, respectively). After adjustment, hip fracture incidence was lower in the suvorexant group, but the association was not significant (HR, 0.57, 95% CI, 0.23-1.44, p = 0.234).

CONCLUSION

DORAs, particularly lemborexant, may be safer alternatives to Z-drugs with respect to hip fracture risk.

Для цитирования: Matsuo Yuichiro, Yamana Hayato, Sasabuchi Yusuke, Matsui Hiroki, Kohro Takahide, Yasunaga Hideo. Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z-Drugs: A Target Trial Emulation.. Journal of the American Geriatrics Society. 2026. DOI: 10.1111/jgs.70754.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.